Amendments to the Claims:

Claims 1-8, 10, 12-19, 21 and 23 are pending and are under examination. Claims 1, 5, 7-8, 10, 12-13, 16, 18-19, 21 and 23 have been amended. Claims 9, 11, 20, 22 and 24-27 are canceled without prejudice or disclaimer. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended): A composition for modulation of LXR function in a cell, said composition comprising a pharmaceutically acceptable excipient and a compound having the formula:

$$A \stackrel{O}{\underset{R^2}{\bigvee}} R^1$$

or a pharmaceutically acceptable salt thereof, wherein

A is a member selected from the group consisting of (C_5-C_{18}) alkyl and (C_5-C_{18}) heteroalkyl;

 R^1 is a member selected from the group consisting of 1-(furan-2-yl)ethyl, 1-(pyridin-2-yl)ethyl, 1-(furan-2-yl)-2-propyl, 1-(2-pyridyl)-2-propyl, 1-(furanyl)isobutyl, 1-(3-pyridyl)isobutyl, 1-(pyridin-4-yl)ethyl, 1-(pyridin-4-yl)isobutyl, and 1-(3-furanyl)-3-butenyl; and (C_3-C_{12}) alkyl, aryl, aryl(C_1-C_8)alkyl, aryl(C_2-C_8)heteroalkyl, (C_3-C_{12}) heteroalkyl, heteroaryl, heteroaryl((C_1-C_8) alkyl and heteroaryl((C_2-C_8) heteroalkyl; and

 R^2 is a member selected from the group consisting of aryl, heteroaryl, aryl(C_1 - C_8)alkyl, heteroaryl(C_1 - C_8)alkyl, aryl(C_2 - C_8)heteroalkyl and heteroaryl(C_2 - C_8)heteroalkyl;

wherein R^{+} and R^{2} are optionally combined together with the nitrogen atom to which each is attached to form a 5, 6, 7 or 8 membered ring, and said compound binds to the ligand binding domain of LXR α with an affinity of at least 1 micromolar.

2. (Original) A composition in accordance with claim 1, wherein A is selected from the group consisting of (C_5-C_{18}) cycloalkyl and (C_5-C_{18}) heterocycloalkyl.

- 3. (Original) A composition in accordance with claim 1, wherein A is selected from the group consisting of (C_8-C_{18}) bicycloalkyl, (C_8-C_{18}) tricycloalkyl, (C_8-C_{18}) heterobicycloalkyl and (C_8-C_{18}) heterotricycloalkyl.
 - 4. (Original) A composition in accordance with claim 1, wherein A is adamantyl.
- 5. (Currently Amended): A composition in accordance with claim 3, wherein R¹ is selected from the group consisting of 1-(furan-2-yl)ethyl and 1-(pyridin-2-yl)ethyl aryl(C₁-C₈)alkyl and heteroaryl(C₁-C₈)alkyl.
- 6. (Currently Amended): A composition in accordance with claim 3, wherein R² is selected from the group consisting of aryl and heteroaryl
- 7. (Currently Amended): A composition in accordance with claim 1, wherein A is adamantyl, R^1 is selected from the group consisting of 1-(furan-2-yl)ethyl, 1-(pyridin-2-yl)ethyl, 1-(furan-2-yl)-2-propyl, 1-(2-pyridyl)-2-propyl, 1-(furanyl)isobutyl, 1-(3-pyridyl)isobutyl, 1-(pyridin-4-yl)ethyl and 1-(pyridin-4-yl)isobutyl-aryl(C_1 - C_8)alkyl and heteroaryl(C_1 - C_8)alkyl and R^2 is selected from the group consisting of aryl and heteroaryl.
- **8.** (Currently Amended): A composition in accordance with claim 1, wherein A is adamantyl, R^1 is selected from 1-(3-furanyl)-3-butenyl heteroaryl(C_3 - C_8)alkenyl and R^2 is selected from phenyl and pyridyl.
 - 9. (Canceled)
- 10. (Currently Amended): A composition in accordance with claim 1, wherein A is adamantyl, R^1 is selected from the group consisting of 1-(furan-2-yl)ethyl and 1-(pyridin-2-yl)ethyl heteroaryl(branched C_2 - C_8)alkyl and R^2 is selected from the group consisting of aryl and heteroaryl.
 - 11. (Canceled)
- 12. (Currently Amended): A composition in accordance with claim 1, wherein A is 1-adamantyl, R^{+} is selected from aryl(C_{1} - C_{8})alkyl and heteroaryl(C_{1} - C_{8})alkyl, and R^{2} is selected from the group consisting of pyridyl, phenyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl and furanyl.
 - 13. (Currently Amended): A compound having the formula:

Appl. No. 09/479,315 Amdt. dated December 19, 2003 Reply to Office Action of August 20, 2003

or a pharmaceutically acceptable salt thereof, wherein

 A^1 is a member selected from the group consisting of (C_5-C_{12}) monocycloalkyl, (C_5-C_{12}) heteromonocycloalkyl, (C_8-C_{18}) bicycloalkyl, (C_8-C_{18}) tricycloalkyl, (C_8-C_{18}) heterobicycloalkyl and (C_8-C_{18}) heterotricycloalkyl;

 R^{11} is a member selected from the group consisting of 1-(furan-2-yl)ethyl, 1-(pyridin-2-yl)ethyl, 1-(furan-2-yl)-2-propyl, 1-(2-pyridyl)-2-propyl, 1-(furanyl)isobutyl, 1-(3-pyridyl)isobutyl, 1-(pyridin-4-yl)ethyl, 1-(pyridin-4-yl)isobutyl, 1-(2-furanyl)-3-butenyl, and 1-(3-furanyl)-3-butenyl; (C_3-C_{12}) alkyl, aryl, aryl(C_1-C_8)alkyl, aryl(C_2-C_8)heteroalkyl, (C_3-C_{12}) heteroalkyl, heteroaryl, heteroaryl((C_1-C_8) alkyl and heteroaryl((C_2-C_8) heteroalkyl; and

 R^{21} is a member selected from the group consisting of aryl, heteroaryl, aryl(C_1 - C_8)alkyl, heteroaryl(C_1 - C_8)alkyl, aryl(C_2 - C_8)heteroalkyl and heteroaryl(C_2 - C_8)heteroalkyl;

and wherein R¹¹ and R²¹ can be combined with the nitrogen atom to which each is attached to form a five- to eight-membered ring, with the following provisos:

when R²⁴ is 2-pyridyl, R¹⁴ is other than a substituted or unsubstituted

2 (1-piperazinyl)ethyl or (tetrahydro-2H-pyrido[3,4-b]indol-2-yl)ethyl group;

when R²⁴ is substituted or unsubstituted phenyl, R¹⁴ and R²⁴ are not combined to form a ring with the attached nitrogen atom; and

when R²¹ is substituted or unsubstituted phenyl, R¹¹ is not allyl, 2-(acylamino)ethyl, or benzyloxycarbonyl.

- 14. (Original) A compound in accordance with claim 13, wherein A^1 is selected from the group consisting of (C_8-C_{18}) bicycloalkyl, (C_8-C_{18}) tricycloalkyl, (C_8-C_{18}) heterobicycloalkyl and (C_8-C_{18}) heterotricycloalkyl.
- 15. (Original) A compound in accordance with claim 13, wherein A^1 is adamantyl.

- 16. (Currently Amended): A compound of claim 13, wherein R¹¹ is selected from the group consisting of 1-(furan-2-yl)ethyl, 1-(pyridin-2-yl)ethyl and 1-(3-furanyl)-3-butenyl aryl(C₁-C₈)alkyl and heteroaryl(C₁-C₈)alkyl.
- 17. (Currently Amended): A compound in accordance with claim 13, wherein R²¹ is selected from the group consisting of aryl and heteroaryl.
- 18. (Currently Amended): A compound in accordance with claim 13, wherein A^1 is adamantyl, R^{11} is selected from the group consisting of 1-(furan-2-yl)ethyl, 1-(pyridin-2-yl)ethyl and 1-(3-furanyl)-3-butenyl-aryl(C_1 - C_8)alkyl-and heteroaryl(C_1 - C_8)alkyl-and R^{21} is selected from the group consisting of aryl and heteroaryl.
- 19. (Currently Amended): A compound in accordance with claim 13, wherein A¹ is adamantyl, R¹¹ is selected from the group consisting of 1-(2-furanyl)-3-butenyl and 1-(3-furanyl)-3-butenyl heteroaryl(C₃-C₈)alkenyl and R²¹ is selected from the group consisting of phenyl and pyridyl.

20. (Canceled)

21. (Currently Amended): A compound in accordance with claim 13, wherein A^1 is adamantyl, R^{11} is selected from the group consisting of 1-(furan-2-yl)ethyl, 1-(pyridin-2-yl)ethyl and 1-(3-furanyl)-3-butenyl heteroaryl(branched C_2 - C_8)alkyl and R^{21} is selected from the group consisting of aryl and heteroaryl.

22. (Canceled)

23. (Currently Amended): A compound in accordance with claim 13, wherein A^1 is 1-adamantyl, R^{11} is selected from the group consisting of 1-(furan-2-yl)ethyl, 1-(pyridin-2-yl)ethyl and 1-(3-furanyl)-3-butenyl-from aryl(C_1 - C_8)alkyl and heteroaryl(C_1 - C_8)alkyl, and R^{21} is selected from the group consisting of pyridyl, phenyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl and furanyl.

24-27. (Canceled)